弗莱卡尼德用于治疗安德森-塔维尔综合征
Tomer D Mann1, Ayhan Yoruk1, Raquel A Neves2
1Department of Cardiology, Univrsity of California-San Francisco (UCSF) Medical Center, San Francisco, California, USA.
JACC. Clinical electrophysiology
|May 15, 2025
概括
弗莱凯尼德在安德森-塔维尔综合征1型 (ATS1) 患者中有效减少心室节律失常和症状. 由于潜在的毒性,仔细监测是必不可少的,但大多数患者能很好地忍受治疗.
科学领域:
- 心脏病学 心脏病学
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 安德森-塔维尔综合征1型 (ATS1) 是一种罕见的遗传疾病,由KCNJ2突变引起,导致危及生命的心律失常.
- 弗莱凯尼德已被提议用于ATS1治疗,但大型研究的证据有限.
研究的目的:
- 评估flekainide在治疗ATS1患者心室节律失常和相关症状方面的疗效和安全性.
- 评估弗莱卡尼德对运动跑步机测试结果和霍尔特监测结果的影响.
主要方法:
- 一项多中心队列研究,涉及31名ATS1患者.
- 来自九个参与中心的临床和遗传数据的收集和聚合分析.
- 随着弗莱卡尼尼德治疗,随访时间中位数为4.2年.
主要成果:
- 弗莱凯尼德显著减少了从18名到5名患者的积极运动跑步机测试 (OR:0.13;P=0.035).
- 在66%的患者中,心室失常得分有所改善,早发心室收缩负担降低了84.8% (P < 0.001).
- 77.7%的有症状的患者变得无症状,其中84%报告没有副作用.
结论:
- 弗莱卡尼德在ATS1患者中表现出有效性和良好的耐受性,用于控制心室心律失常.
- 潜在的毒性需要仔细的剂量定位和通过心电图监测,特别是QRS扩大.
相关概念视频
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
846
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
846
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.1K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.1K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
665
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
665
Disturbances in Heart Rhythm
729
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
729
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
714
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
714
Electroconvulsive Therapy
19
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
19


